ArticleCurrent oncology (Toronto, Ont.)2024

Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer.

Caroline Muñoz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.